The RNF213 gene helps guide how blood vessels grow, stay stable, and respond to stress. This gene plays an important role in keeping arteries open enough for steady blood flow, especially in the brain. Certain variants in the RNF213 gene, especially some that run in families, are linked to moyamoya disease, a condition where brain arteries become narrowed and tiny backup vessels form. Some people carrying an RNF213 variant may also have changes in other blood vessels, but effects vary widely.
What is a gene?
Genes are sections of DNA that hold instructions your cells use to make molecules or manage processes in the body. Some genes carry the directions for producing proteins, which are the working parts of cells. Others mainly regulate when certain processes happen, where they happen, and how active they are. Together, genes affect how the body develops and works, and they can also shape how you respond to food, stress, or medications. For a deeper look at this topic, you can learn more in the LearnHub.
Overview
RNF213Gene function
What if the gene works
The RNF213 gene helps regulate blood vessel growth and maintenance. Its protein also supports how cells respond to stress and handle certain fats.
Risk
What if the gene does not work
Variants in the RNF213 gene are best known for increasing the chance of moyamoya disease, which narrows blood vessels in the brain. Milder and more severe variants can affect onset, severity, and whether broader blood vessel problems appear.
Treatment
What does that mean for your treatment
A pathogenic or loss-of-function variant in the RNF213 gene does not currently point to a specific medicine or management plan. Care is guided by the blood vessel findings and symptoms, not by the gene change alone. Variants in the RNF213 gene are being studied as markers of moyamoya-related vessel changes and disease course, but this has not yet changed routine treatment.
Conditions associated with RNF213
Gene function
What if the gene works
Your cells rely on the RNF213 gene to keep several routine processes running smoothly. Its protein works as both an energy using motor and a cellular tagging tool, helping manage fat storage, internal organization, and blood vessel cell behavior. These everyday jobs support normal cell balance across the body.
Its protein can attach ubiquitin, a small cellular label, to selected targets. This helps cells direct materials to the right place and manage routine cleanup.
This protein uses ATP, the cell's main energy source, to power shape changes. That allows large, organized tasks to happen inside the cell.
Inside cells, it helps regulate lipid droplets, the tiny packages where fat is stored. This supports normal fat handling and keeps those stores organized for daily needs.
The RNF213 gene also helps guide how cells lining blood vessels grow, move, and respond to signals. This supports normal blood vessel development and steady vessel maintenance.
What is a variant?
Within a gene, a genetic variant is a small difference in the DNA sequence. These variants are common and help make up normal human diversity, including differences in appearance, metabolism, and how the body responds to environmental influences. Many have no noticeable effect and simply reflect natural genetic variation. In some cases, though, a variant changes how a gene functions more substantially and may contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
Variants in the RNF213 gene often change how the protein uses energy, joins with itself, and handles protein tagging, a cell process that helps control other proteins. Some RNF213 gene variants, including certain missense changes, may partly alter this activity, while more disruptive variants can reduce it more strongly or make the protein unstable. This range helps explain how RNF213 gene variants affect blood vessel remodeling and why moyamoya-related changes may appear earlier or involve more vessels in some people.
How variants are linked to conditions
Variants in the RNF213 gene are most strongly linked to moyamoya disease, a rare condition that narrows blood vessels at the base of the brain. The connection between the RNF213 gene and moyamoya disease is strongest in East Asian populations, but carrying a variant does not mean you will develop symptoms. Some variants have also been associated with other forms of narrowing in the brain’s arteries.
A variant is not necessarily a diagnosis
Genetic variants are a usual part of human biology and are common throughout the general population. Most do not have a direct effect on health and simply represent natural human diversity. For many genes, carrying a variant associated with a condition indicates a possible link rather than a definite diagnosis, especially when several genes and environmental influences are involved. In some situations, however, a single well-characterized variant in a particular gene is enough to confirm a diagnosis.
Are there things that can increase or change my risk?
For RNF213, risk is mainly shaped by the specific gene change, family history, and ancestry, especially for moyamoya disease, which is more often linked to certain RNF213 changes in East Asian populations. Not everyone with an RNF213 change develops illness, and other genes and life factors likely play a part, but these are still being worked out.
Inheritance of RNF213 variants
The RNF213 gene inheritance pattern can depend on the specific condition and variant involved. For the best known RNF213-related condition, moyamoya disease susceptibility, inheritance is usually autosomal dominant with reduced penetrance. This means a parent carrying a disease linked RNF213 variant can pass it to a child with a 50% chance, but not everyone who inherits the variant develops blood vessel changes or symptoms. In families asking how RNF213 variants are inherited, it helps to know that one changed copy may raise risk, while the health effect can vary widely from person to person.
What does my RNF213 result mean for my family?
Some changes in the RNF213 gene are linked to a condition called moyamoya disease, and this usually follows a dominant family pattern, meaning close relatives can sometimes carry the same change. For many families, this means parents, brothers, sisters, and children may also want to learn whether they have the variant, even if they feel well. Not everyone with an RNF213 variant develops health problems, so the effect in relatives can vary.
Genetic information
Genetic testing
How you find out about variants
For people being evaluated for moyamoya disease, RNF213 genetic testing usually uses a blood or saliva sample, and the lab reads the DNA in the RNF213 gene to look for variants. Results can show whether a known variant is present, which may support diagnosis and family risk assessment, but does not predict symptoms with certainty.
When should I consider getting a genetic test?
Consider testing for changes in the RNF213 gene if you or a close relative has moyamoya disease, a condition where blood vessels in the brain become narrowed, especially with a family history or East Asian background. Testing can help clarify inherited risk, but a result does not predict with certainty who will develop the condition.
A genetic result is only one part of your health story
Genetic results can be informative, but how much they reveal varies with the condition and the type of variant. Over time, many factors influence how the body functions, including lifestyle, environment, age, and medical history. In some conditions, especially those shaped by many genes, genetic information provides context rather than certainty and is most useful when considered together with other parts of care. In other situations, a genetic result can offer a clear answer. In areas like medication response, genetic findings can also help make personal experiences easier to understand.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how people respond to medicines. This helps explain why the same treatment may work well for one person, have less effect for another, or cause more side effects in someone else. Differences in how the body absorbs, breaks down, transports, or responds to a drug are common, and they can influence both benefit and sensitivity.
What is Pharmacogenetics?
Pharmacogenetics explores how differences in genes can affect the way a person responds to medication. It examines connections between genes and drugs to help explain why the same treatment may work differently from one person to another. With many medicines, genes can influence both how strongly a drug works and how the body handles it. This information can help support more informed, more individualized treatment decisions. More detailed information on this topic is available in the LearnHub.
Drugs influenced by the RNF213 gene
When should I seek medical advice?
There is not yet a broadly confirmed role for this gene in guiding medicine response, so it is best to speak with your doctor if you have health concerns, new symptoms, or questions about side effects or treatment changes.
History
For many years, doctors noticed that moyamoya disease sometimes appeared in several members of the same family, suggesting an inherited cause. In 2011, Japanese research groups identified the RNF213 gene as a major genetic link to this condition, marking an important step in understanding why it clusters in some families. Building on this early work, scientists found that one variant, RNF213 p.R4810K, was especially common in East Asian people with moyamoya disease. This discovery helped explain long observed regional patterns, particularly in Japan, Korea, and China. Later studies showed that the RNF213 gene could also be relevant in some people outside East Asia, broadening the historical picture. Each stage in history has added to the picture we have today.